Summary
Prostacyclin is a potent but unstable vasodilator, and inhibitor of platelet aggregation, which is produced by blood vessel walls. Platelet aggregability may be constantly conditioned in vivo by local or circulating prostacyclin. Prostacyclin is important in the maintenance of vascular homeostasis and may be implicated in certain disease states. The use of prostacyclin in antithrombotic therapy appears logical, considering its action in increasing platelet cyclic AMP and reducing aggregation; its potential in antithrombotic therapy is presently being explored.
Similar content being viewed by others
References
Bunting, S. and Moncada, S.: Prostacyclin by preventing platelet activation prolongs activated clotting time in blood and platelet rich plasma and potentiates the anticoagulant effect of heparin. British Journal of Pharmacology 69: 268P–269P (1980).
Bunting, S.; Moncada, S.; Vane, J.R.; Woods, H.F. and Weston, M.J.: Prostacyclin improves hemocompatibility during charcoal haemoperfusion; in Vane and Bergstom (Eds) Prostacyclin, pp.361–369 (Raven Press, New York 1979).
FitzGerald, G.A.; Friedman, L.A.; Miyamori, I.; O’Grady, J. and Lewis, P.J.: A double blind placebo controlled crossover study of prostacyclin in man. Life Sciences 25: 665–672 (1979).
Gimson, A.E.S.; Hughes, R.D.; Mellon, P.J.; Woods, H.F.; Langley, P.G.; Canalese, J.; Williams, R. and Weston, M.J.: Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1: 173–175 (1980).
Glavind, J.; Hartmann, S.; Clemmesen, J.; Jessen, K.E. and Dam, H.: Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathologica et Microbiologica Scandinavica 30: 1–3 (1952).
Gorman, R.R.; Bunting, S. and Miller, O.V.: Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377–388 (1977).
Gryglewski, R.J.; Korbut, R. and Ocetkiewicz, A.C.: Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature (London) 273: 765–767 (1978).
Hensby, C.N.; Barnes, P.J.; Dollery, C.T. and Dargie, H.: Production of 6-oxo-PGF1α by human lung in vivo. Lancet 2: 1162–1163 (1979).
Johnson, R.A.; Morton, D.R.; Kinner, J.H.; Gorman, R.R.; McGuire, J.C.; Sun, F.F.; Whittaker, N.; Bunting, S.; Salmon, J.; Moncada, S. and Vane, J.R.: The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12: 915–928 (1976).
Longmore, D.B.; Bennett, G.; Gueirrara, D.; Smith, H.; Bunting, S., Moncada, S.; Reed, P.; Read, N.G. and Vane, J.R.: Prostacyclin: A solution to some problems of extracorporeal circulation. Lancet 2: 1002–1005 (1979).
Marcus, A.J.: Role of lipids in platelet function with particular reference to the arachidonic acid pathway. Journal of Lipid Research 19: 793–826 (1978).
Moncada, S. and Vane, J.R.: The discovery of prostacyclin — a fresh insight into arachidonic acid metabolism; in Kharasch and Fried (Eds) Biochemical Aspects of Prostaglandins and Thromboxanes, pp.155–177 (Academic Press, New York, San Francisco, London 1977).
Moncada, S. and Vane, J.R.: Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. New England Journal of Medicine 300: 1142–1147 (1979a).
Moncada, S. and Vane, JR.: Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacological Reviews 30(3): 293–331 (1979b).
Moncada, S.; Gryglewski, R.J.; Bunting, S. and Vane, J.R.: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (London) 263: 663–665 (1976).
Moncada, S.; Korbut, R.; Bunting, S. and Vane, J.R.. Prostacyclin is a circulating hormone. Nature (London) 273: 767–768 (1978).
Mustard, J.F. and Packham, M.A.: Platelets, thrombosis and drugs. Drugs 9: 19–76 (1975).
Nordoy, A.; Svensson, B.; Wiebe, D. and Hoak, J.C.: Lipoproteins and the inhibitory effect of human endothelial cells on platelet function. Circulation Research 43: 527–534 (1978).
O’Grady, J.; Warrington, S.; Moti, M.J.; Bunting, S.; Flower, R.; Fowle, A.S.E.; Higgs, E.A. and Moncada, S.: Effects of intravenous prostacyclin infusions in healthy volunteers — some preliminary observations; in Vane and Bergstrom (Eds) Prostacyclin, pp.409–417 (Raven Press, New York 1979).
O’Grady, J.; Warrington, S. and Moti, M.J.: Effects of intravenous infusion of prostacyclin in man. Prostaglandins 19: 319–332 (1980).
Remuzzi, G.; Cavenaghi, A.E.; Mecca, G.; Donati, M.B. and De Gaetano, G.: Prostacyclin (PGI2) and bleeding time in uremic patients. Thrombosis Research 11: 919–920 (1977).
Remuzzi, G.; Misiani, R.; Marchesi, D.; Livio, M; Mecca, G.; De Gaetano, G. and Donati, M.B.: Haemolytic-uraemic syndrome: Deficiency of plasma factor(s) regulating prostacyclin activity. Lancet 2: 871–872 (1978).
Salzman, E.W.; Rosenberg, R.D.; Smith, M.H.; Lindon, J.N. and Favreau, L: Effect of heparin and heparin fractions on platelet aggregation. Journal of Clinical Investigation 65: 64–73 (1980).
Szczeklik, A.; Gryglewski, R.J.; Musial, J.; Grodzinska, L.; Serwonska, M. and Marcinkiewicz, E.: Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thrombosis and Haemostasis 40: 66–74 (1978a).
Szczeklik, A.; Gryglewski, R.J.; Nizankowski R.; Musial, J.; Pieton, R. and Mruk, J.: Circulatory and anti-platelet effects of intravenous prostacyclin in healthy man. Pharmacological Research Communications 10: 545–556 (1978b).
Tateson, J.E.; Moncada, S. and Vane, J.R.: Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13: 389–399 (1977).
Vermylen, J.; Chamone, D.A.F. and Verstraete, M.: Stimulation of prostacyclin release from vessel wall by BAYg6575, an antithrombotic compound. Lancet 1: 518–520 (1979).
Verstraete, M. and Verwilghen, R.: Haematological disorders; in Avery (Ed) Drug Treatment, 2nd Edition, pp.889–952 (ADIS Press, Sydney and Churchill Livingstone, Edinburgh 1980).
Woods, H.F.; Ash, G.; Weston, M.J.; Bunting, S.; Moncada, S. and Vane, J.R.: Prostacyclin can replace heparin in haemodialysis in dogs. Lancet 2: 1075–1077 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moncada, S., Vane, J.R. Prostacyclin and Blood Coagulation. Drugs 21, 430–437 (1981). https://doi.org/10.2165/00003495-198121060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198121060-00002